Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pan African Resources

    MCap

    GBP695m

    Last close

    GBP0.36

    ▲ 0.95 (2.69%)

    Quadrise

    MCap

    GBP28m

    Last close

    GBP0.02

    ▲ −0.17 (−10.00%)

    Sareum Holdings

    MCap

    GBP33m

    Last close

    GBP0.26

    ▲ −1.25 (−4.59%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Cantargia (OMX: CANTA)

Last close As at 20/11/2024

SEK1.83

▲ −0.02 (−1.08%)

Market capitalisation

SEK336m

Cantargia is a clinical-stage biotech company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Understanding of inflammation in cancer indicates that cytokines are produced not only by immune cells, but also by cancer cells to evade immune responses, making cytokines promising oncology targets. Further, recent Phase II data for AbbVie’s lutikizumab has increased interest in Cantargia’s CAN10, as it blocks IL-33 and IL-36 in addition to IL-1.

Latest Insights

View More

Healthcare | Flash note

Cantargia — Encouraging data for nadunolimab in CANFOUR

Healthcare | Flash note

Cantargia — First patient treated in Phase II part of TRIFOUR

Healthcare | Update

Cantargia — Next phase of clinical development in sight

Healthcare | Update

Cantargia — Strong momentum in first nine months of FY22
Visit Website

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Key Management

  • Goran Forsberg

    CEO

Balance Sheet

Forecast net debt (SEKm)

N/A

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (38.6) (51.3) (52.2)
Relative (35.1) (49.5) (58.2)
52 week high/low SEK5.0/SEK1.8

Financials

Cantargia is developing antibodies against IL1RAP. Interim data from CANFOUR (Phase Ib/IIa) in NSCLC and PDAC suggest that nadunolimab could be synergistic with chemotherapy; the latest update (ESMO 2024) showed encouraging survival data in 40 NSCLC patients. Supportive clinical/biomarker data for PDAC have also been reported and Cantargia is preparing for a Phase IIb trial in PDAC. It shared positive data from TRIFOUR (Phase Ib portion), assessing nadunolimab in triple-negative breast cancer; the Phase II portion is ongoing with initial results expected in H125. A new Phase Ib/IIa clinical trial for nadunolimab in leukaemia is expected to start in Q424. A second programme, CAN10 (Phase I), is ongoing in autoimmune diseases. Following encouraging safety/biomarker data from the SAD cohort, the MAD part of CAN10 is now underway. At end-Q224, Cantargia had c SEK105m in cash and short-term investments.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2022A 0.0 (377.9) (371.8) (290.43) N/A N/A
2023A 0.0 (286.6) (280.0) (164.94) N/A N/A
2024E N/A N/A N/A N/A N/A N/A
2025E N/A N/A N/A N/A N/A N/A

Research

Flash note

Healthcare

Cantargia — First patient treated in Phase II part of TRIFOUR

Update

Healthcare

Cantargia — Next phase of clinical development in sight

Healthcare

Flash note

Cantargia — Encouraging data for nadunolimab in CANFOUR

Update

Healthcare

Cantargia — Strong momentum in first nine months of FY22

Flash note

Healthcare

Cantargia — New data support differentiation of nadunolimab

Flash note

Cantargia — Recruitment milestone achieved

Flash note

Healthcare

Cantargia — First patient treated under CIRIFOUR trial

Update

Healthcare

Cantargia — A positive H122 supports clinical activity

edison tv

Healthcare

Cantargia – executive interview

Flash note

Healthcare

Cantargia — Announcement of rights issue

Flash note

Healthcare

Cantargia — ASCO data do not disappoint
View All

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Outlook for 2024: Life sciences – where has the conviction gone?

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare
volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 
View All

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free